Document:

EX-4.2

 Exhibit 4.2 

FORM OF 4.10% SENIOR NOTE DUE 2047 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY
OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE TRANSFERRED TO, OR REGISTERED OR EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED IN THE NAME OF, ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, AND NO SUCH TRANSFER MAY BE
REGISTERED, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. EVERY SECURITY AUTHENTICATED AND DELIVERED UPON REGISTRATION OF TRANSFER OF, OR IN EXCHANGE FOR OR IN LIEU OF, THIS SECURITY SHALL BE A GLOBAL SECURITY SUBJECT TO THE
FOREGOING, EXCEPT IN SUCH LIMITED CIRCUMSTANCES. 
 UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK,
S.A./N.V., AS OPERATOR OF THE EUROCLEAR SYSTEM (“EUROCLEAR”) AND CLEARSTREAM BANKING S.A. (“CLEARSTREAM” AND, TOGETHER WITH EUROCLEAR, “EUROCLEAR/CLEARSTREAM”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER,
EXCHANGE OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK) LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED
OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, USB NOMINEES
(UK) LIMITED, HAS AN INTEREST HEREIN. 
 TRANSFERS OF THIS NOTE ARE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF THE
DEPOSITARY OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL SECURITY ARE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE TRANSFER PROVISIONS OF THE INDENTURE. 

 INTEL CORPORATION 

4.10% Senior Notes due 2047 
  

			
	No. [●]	 	ISIN No.: XS1661884400
		 	Initially $[●]

 INTEL CORPORATION, a Delaware corporation (the “Issuer”), for value received promises to pay
to USB Nominees (UK) Limited, as nominee of Elavon Financial Services DAC, a common depositary for the accounts of Euroclear Bank S.A./N.V. and Clearstream Banking S.A. or registered assigns, the principal sum of $[●] on August 14, 2047.

 Interest Payment Dates: February 14 and August 14 of each year (each, an “Interest Payment Date”),
commencing on February 14, 2018. 
 Interest Record Dates: January 31 and July 31 (each, a “Regular Record
Date”). 
 Reference is made to the further provisions of this Note contained herein, which will for all purposes have the same
effect as if set forth at this place. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

			
	 INTEL CORPORATION

		
	 By:
	 	 
		 	 Name: Ravi Jacob

		 	 Title:   Vice President and Treasurer

  
 [Signature Page to
Note] 

 This is one of the Notes of the series designated herein and referred to in the within-mentioned
Indenture. 
 Dated: August 14, 2017 
  

			
	 WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee

		
	 By:
	 	 
		 	 Authorized Signatory

  
 [Signature Page to
Note] 

 (REVERSE OF NOTE) 

INTEL CORPORATION 
 4.10% Senior
Notes due 2047 
 1. Interest. 

Intel Corporation (the “Issuer”) promises to pay interest on the principal amount of this Note at the rate per annum described
above. Cash interest on the Notes will accrue from the most recent date to which interest has been paid; or, if no interest has been paid, from August 14, 2017. Interest on this Note will be paid to but excluding the relevant Interest Payment
Date or on such earlier date as the principal amount shall become due in accordance with the provisions hereof. The Issuer will pay interest semi-annually in arrears on each Interest Payment Date, beginning on June 14, 2016. If any Interest
Payment Date, Stated Maturity, Redemption Date or other payment date with respect to the Notes is not a Business Day, the required payment of principal, premium, if any, or interest will be due on the next succeeding Business Day as if made on the
date that such payment was due, and no interest will accrue on that payment for the period from and after that Interest Payment Date, Stated Maturity, Redemption Date or other payment date, as the case may be, to the date of that payment on the next
succeeding Business Day. Interest will be computed on the basis of a 360-day year consisting of twelve 30-day months. 

The Issuer shall pay interest on overdue principal from time to time on demand at the rate borne by the Notes and at the same rate on overdue
installments of interest (without regard to any applicable grace periods) to the extent lawful from the dates such amounts are due until such amounts are paid or made available for payment. 

2. Paying Agent. 
 Initially,
Elavon Financial Services DAC, UK Branch, will act as paying agent (the “Paying Agent”). The Issuer may appoint and change the Paying Agent without notice to the Holders. 

3. Indenture; Defined Terms. 

This Note is one of the 4.10% Senior Notes due 2047 (the “Notes”) issued under the Indenture dated as of March 29,
2006, as amended by the First Supplemental Indenture dated as of December 3, 2007 (together, the “Base Indenture”) by and between the Issuer and Wells Fargo Bank, National Association, as Trustee (the
“Trustee”) and, as amended, modified and supplemented by the Eleventh Supplemental Indenture dated as of August 14, 2017 (the “Eleventh Supplemental Indenture” and, together with the Base Indenture, the
“Indenture”), by and among the Issuer, the Trustee and the Paying Agent. This Note is a “Security” and the Notes are “Securities” under the Indenture. 

  
 R-1 

 For purposes of this Note, unless otherwise defined herein, capitalized terms herein are used as
defined in the Indenture. The terms of the Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939 (15 U.S.C. Sections 77aaa-77bbbb) (the “TIA”) as in effect
on the date on which the Indenture was qualified under the TIA. Notwithstanding anything to the contrary herein, the Notes are subject to all such terms, and Holders of Notes are referred to the Indenture and the TIA for a statement of them. To the
extent the terms of the Indenture and this Note are inconsistent, the terms of the Indenture shall govern. 
 4. Denominations; Transfer;
Exchange. 
 The Notes are in registered form, without coupons, in denominations of $100,000 and multiples of $1,000 in excess thereof. A
Holder shall register the transfer or exchange of Notes in accordance with the Indenture. The Issuer may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay certain transfer taxes or similar
governmental charges payable in connection therewith as permitted by the Indenture. The Issuer need not issue, authenticate, register the transfer of or exchange any Notes for a period of fifteen (15) days before the electronic delivery or
mailing of a notice of redemption, nor need the Issuer register the transfer or exchange of any Note selected for redemption. 
 5.
Amendment; Modification; Waiver. 
 The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Issuer and the rights of the Holders of the Notes affected under the Indenture at any time by the Issuer and the Trustee with the consent of the Holders of not less than a majority in aggregate
principal amount of the Notes and each other series of Securities at the time Outstanding affected thereby (voting together as a single class)s. The Indenture contains provisions permitting the Holders of not less than a majority in principal amount
of the Securities of a series at the time Outstanding with respect to which a default under the Indenture shall have occurred and be continuing, on behalf of the Holders of all Securities of such series, to waive, with certain exceptions, such past
default with respect to such series and its consequences. The Indenture also permits the Holders of not less than a majority in aggregate principal amount of all series of Securities (including the Notes) at the time Outstanding affected (voting
together as a single class), on behalf of the Holders of all such Securities, to waive future compliance by the Issuer with certain provisions of the Indenture. Any such consent or waiver by the Holder of this Note shall be conclusive and binding
upon such Holder and upon all future Holders of this Note and of any Security issued upon the registration of transfer hereof or in exchange therefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note.
Without notice to or consent of any Holder, the Indenture also permits the amendment or supplement thereof to, among other things, cure any ambiguity, defect or inconsistency or comply with any requirements of the Commission in connection with
qualifications of the Indenture under the TIA, or make any other change that does not adversely affect the rights of Holders in any material respect. 

  
 R-2 

 6. Optional Redemption. 

On each August 14 on or after August 14, 2022, the Issuer may redeem the Notes at its option in whole, but not in part, at a
Redemption Price equal to 100% of their principal amount plus any accrued interest to, but not including, the Redemption Date, as set forth in the Eleventh Supplemental Indenture. 

7. Redemption for Tax Reasons. 

The Notes are redeemable by the Issuer in whole, but not in part, upon the occurrence of certain developments affecting U.S. taxation
constituting a Change in Tax Law described in the Eleventh Supplemental Indenture at a Redemption Price equal to 100% of their principal amount (plus any accrued interest and Additional Amounts then payable with respect to the Notes). 

8. Payment of Additional Amounts. 

The Issuer, will, subject to the exceptions and limitations set forth in the Eleventh Supplemental Indenture, pay to or on account of any
beneficial owner of Notes who is not a U.S. Person such Additional Amounts as may be necessary to ensure that the net amount received by such beneficial owner, after withholding or deduction for Taxes, will be equal to the amount such person would
have received in the absence of such withholding or deduction. 
 As used in this Section 8, “U.S. Person” means any
individual who is a citizen or resident of the United States for U.S. federal income tax purposes, a corporation, partnership or other entity created or organized in or under the laws of the United States, any state of the United States or the
District of Columbia, or any estate or trust the income of which is subject to United States federal income taxation regardless of its source. 

9. Defaults and Remedies. 
 If an
Event of Default with respect to the Notes occurs and is continuing, then in every such case the Trustee or the Holders of not less than 25% in principal amount of the Outstanding Notes may declare the principal amount of all the Notes to be due and
payable immediately, by a notice in writing to the Issuer (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) shall become immediately due and payable. 

The Indenture permits, subject to certain limitations therein provided, Holders of not less than a majority in aggregate principal amount of
the Outstanding Notes to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee, with respect to the Notes. 

10. Authentication. 
 This Note
shall not be valid until the Trustee manually signs the certificate of authentication on this Note. 

  
 R-3 

 11. Abbreviations and Defined Terms. 

Customary abbreviations may be used in the name of a Holder of a Note or an assignee, such as: TEN COM (= tenants in common), TEN ENT
(= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act). 

12. ISIN Numbers. 
 Pursuant to a
recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Issuer has caused ISIN numbers to be printed on the Notes as a convenience to the Holders of the Notes. No representation is made as to the accuracy of
such numbers as printed on the Notes and reliance may be placed only on the other identification numbers printed hereon. 
 13. Governing
Law. 
 The laws of the State of New York shall govern the Indenture and this Note without regard to conflicts of laws principles thereof.

  
 R-4 

 ASSIGNMENT FORM 

To assign this Note, fill in the form below: 
 I or we assign
and transfer this Note to 
 (Print or type assignee’s name, address and zip code) 

(Insert assignee’s soc. sec. or tax I.D. No.) 

and irrevocably appoint                  agent to transfer this Note on the
books of the Issuer. The agent may substitute another to act for him. 
  

									
	 	 	 	 	 
	Date:	 	 	 		 	Your Signature:	 	 
					
	 	 	 	 	 	 	 	 	 
	Sign exactly as your name appears on the other side of this Note.	 		 	
		 		 	
					
		 		 		 	 	 	 
		 		 		 	
            Signature

	 Signature Guarantee:
	 		 	
					
	 	 	 	 		 	 	 	 
	Signature must be guaranteed	 		 	
            Signature

 Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the
Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee program” as may be determined by the Registrar in addition to,
or in substitution for, STAMP, all in accordance with the United States Securities Exchange Act of 1934, as amended. 

  
 R-5 

 SCHEDULE OF EXCHANGES OF NOTES 

The following exchanges of a part of this Global Security for certificated Notes or a part of another Global Security have been made: 

 

									
	 Date of

Exchange
	 	 Amount of decrease

in principal amount
 of this
Global Security
	 	 Amount of increase

in principal amount
 of this
Global Security
	  	 Principal amount of

this Global Security

following such
 decrease
(or
 increase)
	  	 Signature of

authorized officer of

Trustee

  
 R-6Exhibit 10.1

 

INSTRUMENT OF GRANT OF NONQUALIFIED
STOCK OPTION

 

INSTRUMENT
OF GRANT dated as of the ___ day of __________, 20___ from TechPrecision Corporation, a Delaware corporation (the “Company”),
to __________ (“Optionee”).

 

W I T N E S
S E T H:

 

WHEREAS,
on __________, 20___, the Company granted Optionee an option to purchase ____________ (_______) shares of the Company’s common
stock, par value $.0001 per share (“Common Stock”), pursuant to the Company’s
2016 Equity Incentive Plan (the “Plan”), and

 

WHEREFORE, the Company
does hereby grant to the Optionee the following Option:

 

1.
Stock Option. Subject
to the terms and conditions set forth in this Instrument of Grant, the Company hereby grants to the Optionee a non-qualified stock
option (the “Option”)
to purchase from the Company ____________ (_______) shares (the “Optioned
Shares”) of Common Stock at an exercise price (the “Exercise Price”) of _______ ($_____) per share,
being not less than the fair market value per share on the date of this Agreement.

 

2. Exercise
Period. The Option shall vest, in accordance with the Company’s 2016 Equity Incentive Plan, and become exercisable as
follows; ___________________, and shall expire and terminate, subject to early termination as provided in Section 3 of this
Instrument of Grant, at 5:00 P.M. Eastern time on __________, 20___ (the “Exercise
Period”); provided, however, that if such date is a day on which banks in the State of New York are authorized
or permitted to be closed, then the Exercise Period shall end at 5:00 P.M. Eastern time on the next day which is not such a day.

 

3. Termination.
This Option shall terminate, and Optionee shall have no further rights under this Option, upon the first to occur of (a) The last
day of the Exercise Period as set forth in Section 2 of this Instrument of Grant, or (b) seven (7) months from the date
Optionee ceases to be a director if Optionee ceases to be a director other than as a result of his death or Disability or (c) twelve
(12) months after the date of death or Disability. In no event may this Option be exercised subsequent to the 5:00 P.M. on the
last day of the Exercise Period.

 

4. Manner
of Exercise.

 

(a) The
Option shall be exercised by written notice of exercise in the form of Exhibit A to this Instrument of Grant addressed to
the Company and signed by the Optionee and delivered to the Company along with this Instrument of Grant and payment in full of
the Exercise Price of the Optioned Shares as to which the Option is being exercised. If the Option is exercised in part only, the
Company will either issue a new Instrument of Grant with respect to the unexercised portion of the Option or shall make a notation
on this Instrument of Grant reflecting the partial exercise.

 

(b)
The Exercise Price is payable by certified or official bank check or by personal check;
provided, however,
that no Optioned Shares shall be issued to Optionee, and Optionee shall have
no rights of a stockholder with respect to the Optioned Shares until the Company has been advised by its bank that the check has
cleared.

 

(c)
The Option may also be exercised by the delivery to the Company of shares
of Common Stock having a fair market value, as of the date of exercise, equal to the Exercise Price of the Optioned Shares to the
extent that the Option is being exercised.

 

     

     

    

 

(d)           (i) In the event of the merger or consolidation of the Company with or into
any corporation or other entity or in the event of the sale by the Company of all or substantially all of its business and assets
followed by a distribution of assets to the stockholders in connection with a liquidation or partial liquidation of the Company
or in the event of a similar transaction (each a “Merger Transaction”),
prior to the expiration of this Option, this Option shall be converted into
the consideration payable with respect to the Common Stock in the Merger Transaction (the “Merger Consideration”)
as follows.

 

(ii)
The Optionee shall receive Merger Consideration having a value equal to the appreciation, if any,
of this Option. The appreciation of this Option shall be determined by multiplying
the number of shares subject to this Option by the difference between (i) the value of the Merger Consideration payable with respect
to one share of Common Stock and (ii) the Exercise Price of this Option. If the value of the Merger Consideration shall be equal
to or less than the Exercise Price, this
Option shall not be converted into Merger Consideration, but
shall terminate, to the
extent not exercised, at the effective time of the Merger Transaction.

 

(iii) The
consideration payable to the Optionee shall be in the same form as the Merger Consideration. If the Merger Consideration shall
consist of both cash and non-cash consideration, the consideration payable upon conversion of this Option shall be a combination
of cash and non-cash consideration in the same proportion as the Merger Consideration is payable to the holders of the Common Stock.

 

(iv) If
and to the extent that the Merger Consideration is other than cash, the value of the non-cash Merger Consideration shall be determined
in good faith by the Company’s Board of Directors, and the Company shall promptly advise the Optionee of such determination.
If the Optionee disagrees with the determination of the Board of Directors, the Optionee shall have the right to exercise this
Option by paying the Exercise Price as provided in Section 4(b) or (c) of this Instrument of Grant prior to the effectiveness
of the Merger Transaction. If the Option is not exercised prior to the effectiveness of the Merger Transaction, the Option shall
be automatically converted or terminated, as the case may be, as provided in this Section 4(d).

 

(e)
The Optioned Shares, when issued upon exercise of the Option, will be duly
and validly authorized and issued, fully paid and non-assessable.

 

(f)
In connection with any exercise of this Option, the Optionee shall, contemporaneously
with the exercise of this Option, to the extent required by law, pay or provide for payment of any withholding taxes due as a result
of such exercise.

 

5.
Adjustment Provisions. The number of shares of Common Stock subject
to the Option and the Exercise Price shall be adjusted in accordance with generally accepted accounting principles in the event
of a stock dividend, stock
split, stock distribution,
reverse split or other combination of shares, recapitalization or otherwise,
which affects the Common Stock.

 

6.
Transferability. The Option is not transferable by the Optionee except
that, in the event of
Optionee’s death or incompetence, the Option may be exercised by Optionee’s legal representative or by the persons
to whom the Option is transferred by will or the laws of descent and distribution.

 

7.
No Rights as a Stockholder. The
Optionee shall have no
interest in and shall not be entitled to any voting rights or any dividend or other rights or privileges of a stockholder of the
Company with respect to any shares
of Common Stock issuable upon exercise of this Option prior to the exercise of this Option and payment of the Exercise Price of
the Optioned Shares.

 

     

     

    

 

8. No
Rights to Continued Service. Nothing in this Instrument of Grant shall be constructed as an employment or consulting agreement.

 

9.
Legality. Anything
in this Option to the contrary notwithstanding, the
Optionee agrees that he or she will not exercise the Option, and
that the Company will not be obligated to issue any shares of Common Stock pursuant to this Option,
if the exercise of the Option or the issuance of such shares shall constitute
a violation by the Optionee
or by the Company of any provisions of any law or of any regulation of any governmental authority. Any determination by the Board
of Directors or the Compensation Committee (the “Committee”) of the Board of Directors,
if appointed, shall
be final, binding and
conclusive. The Company shall not be obligated to take any affirmative action in order to cause the exercise of the Option or the
issuance of shares pursuant thereto to comply with such law or regulation.
The Optionee understands that,
unless the issuance of the Optioned Shares is registered pursuant to the Securities
Act of 1933, as amended
(the “Securities Act”), the
Optioned Shares, if and
when issued, will be
restricted securities, as
defined in Rule 144 of the Securities and Exchange Commission pursuant to the Securities Act. The Company shall not be required
to issue any Optional Shares if the issuance thereof is not permitted pursuant to the Securities Act or if the Optioned Shares
are not registered pursuant to the Securities Act.

 

10.
Action by Company. The existence of the Option shall not effect in any way the right or power
of the Company or its stockholders to make or authorize any or all adjustments,
recapitalization, reorganizations
or other changes in the Company’s capital
structure or its business, or
any merger or consolidation of the Company, or
any issue of bonds, debentures,
preferred or prior preference stocks ahead
of or affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the Company,
or any sale or transfer of all or any part of its assets or business,
or any other corporate act or proceeding,
whether of a similar character or otherwise.

 

11.
Interpretation. As a condition of the granting of the Option,
the Optionee and each person who succeeds to the Optionee’s rights hereunder,
agrees that any dispute or disagreement which shall arise under or as a result of or pursuant to this Option shall be determined
by the Committee in its sole discretion and that any interpretation by the Committee of the terms of this Instrument of Grant shall
be final, binding and
conclusive. If no Committee
is acting, its functions
shall be performed by the Board of Directors, and
each reference in this Option to the Committee shall, in that event, be
deemed to refer to the Board of Directors.

 

12.
Notice. Any notice which either party hereto may be required or permitted to give to the other
shall be in writing, and
any be delivered personally or by mail, postage
prepaid , addressed as
follows:

 

		If to the Company:	TechPrecision Corporation

1 Bella Drive

Westminster, MA 01473

Attention:
Chief Financial Officer

 

or at such other address
as the Company, by
notice, may designate
in writing from time to time

 

		If
                              to the Optionee:	at the address shown on
the records of the Company or at such other address as the Optionee, by
notice to the Company, may designate in
writing from time to time.

 

[Signature Page Follows]

 

     

     

    

 

IN WITNESS
WHEREOF, the Company has executed this Instrument of Grant as of the date first above written.

 

	 	TECHPRECISION CORPORATION
	 	 	 
	 	 	 
	 	By: 	 
	 	 	Thomas Sammons, Chief Financial Officer
	 	 	 
	 	 	 
	 	 	 
	 	OPTIONEE
	 	 	 
	 	 	 
	 	 
	 	[NAME]
	 	(Signature)
	 	 	 
	 	 	 
	 	 	 
	 	 
	 	 
	 	(Address)

 

    
[Signature Page to Instrument of Nonqualified Stock Option]

     

    

 

Exhibit A

 

Date:

 

TechPrecision Corporation

1 Bella Drive

Westminster, MA 01473

 

		Re:	Stock Option Exercise - Instrument of Grant Dated
as of                 , 20

 

Ladies and Gentlemen:

 

I hereby exercise the above-referenced
option to the extent of shares, and I am tendering with this Notice full payment of the Exercise Price in the manner provided in
Paragraph 4 of the Instrument of Grant with respect to the Optioned Shares as to which this Option is being exercised. I further
represent and warrant to the Company that I am aware of the tax consequences of my exercise of the option.

 

	 	Very truly yours,
	 	 
	 	 
	 	 
	 	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]